Evidence map›Paper›PMID 36421156›Full record

ReviewBiosensors2022

CRISPR-Cas-Integrated LAMP.

Nazente Atçeken, Defne Yigci, Berin Ozdalgic, Savas Tasoglu

Abstract readReview
In one paragraph

Review in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. A review on the mechanism and potential diagnostic application of CRISPR/Cas13a system.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  12. Article
  13. Mpox disease, diagnosis, and point of care platforms.Bioengineering & translational medicine · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nazente AtçekenKoç University Translational Medicine Research Center (KUTTAM), Koç University, Istanbul 34450, Turkey.ORCID 0000-0002-2020-9659
Defne YigciSchool of Medicine, Koç University, Istanbul 34450, Turkey.
Berin OzdalgicKoç University Translational Medicine Research Center (KUTTAM), Koç University, Istanbul 34450, Turkey.
Savas TasogluKoç University Translational Medicine Research Center (KUTTAM), Koç University, Istanbul 34450, Turkey.ORCID 0000-0003-4604-217X

Funding

Marie Skłodowska-Curie Individual Fellowship 101003361Royal Academy Newton-Katip Çelebi Transforming Systems Through Partnership award 120N019Tubitak 2232 International Fellowship for Outstanding Researchers Award 118C391
6 · The paper itself

Abstract

Pathogen-specific point-of-care (PoC) diagnostic tests have become an important need in the fight against infectious diseases and epidemics in recent years. PoC diagnostic tests are designed with the following parameters in mind: rapidity, accuracy, sensitivity, specificity, and ease of use. Molecular techniques are the gold standard for pathogen detection due to their accuracy and specificity. There are various limitations in adapting molecular diagnostic methods to PoC diagnostic tests. Efforts to overcome limitations are focused on the development of integrated molecular diagnostics by utilizing the latest technologies available to create the most successful PoC diagnostic platforms. With this point of view, a new generation technology was developed by combining loop-mediated isothermal amplification (LAMP) technology with clustered regularly interspaced short palindromic repeat (CRISPR)-associated (CRISPR-Cas) technology. This integrated approach benefits from the properties of LAMP technology, namely its high efficiency, short turnaround time, and the lack of need for a complex device. It also makes use of the programmable function of CRISPR-Cas technology and the collateral cleavage activity of certain Cas proteins that allow for convenient reporter detection. Thus, this combined technology enables the development of PoC diagnostic tests with high sensitivity, specificity, and ease of use without the need for complicated devices. In this review, we discuss the advantages and limitations of the CRISPR/Cas combined LAMP technology. We review current limitations to convert CRISPR combined LAMP into pathogen-specific PoC platforms. Furthermore, we point out the need to design more useful PoC platforms using microfabrication technologies by developing strategies that overcome the limitations of this new technology, reduce its complexity, and reduce the risk of contamination.

Indexed as

CRISPR-Cas SystemsNucleic Acid Amplification TechniquesMolecular Diagnostic TechniquesPoint-of-Care Testingclustered regularly interspaced short palindromic repeat (CRISPR)-associated (CRISPR-Cas)CRISPR/Cas combined LAMP technologyloop-mediated isothermal amplification (LAMP)point-of-care (PoC) platform

Identifiers

PMID36421156
PMCPMC9688180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.